ClinicalTrials.gg
CompletedNCT00216190Updated Jul 23, 2015

A Safety and Efficacy Study of Dexmedetomidine in ICU Patients Requiring Continuous Sedation

A Phase 4 interventional study of Dexmedetomidine HCL Injection and Midazolam Injection in Mechanically Ventilated and Intubated Subjects, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Completed at 96 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-23.

Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine in ICU subjects who are initially intubated, mechanically ventilated and require sedation for beyond 24 hours.

Read the detailed description

Traditional agents such benzodiazepines and propofol have long been used to sedate critically ill patients. Unfortunately, these agents have serious disadvantages that may have a negative impact on patient outcomes. These disadvantages include respiratory depression, prolonged mechanical ventilation, paradoxical agitation, myocardial depression, hypotension, tachyphylaxis, physical dependence, and an unpredictable duration of action following long term infusions. Additionally, concomitant use of an opioid or other analgesic is often required for ICU patients to achieve adequate levels of pain relief, which may also prolong awakening and possibly increase respiratory depression.

Dexmedetomidine may offer a new treatment option that remedies many of the deficiencies of traditional sedatives. This agent would provide for accurate, titratable sedation and analgesia without the concurrent respiratory depression and accumulation common to other agents. It may permit greater patient interaction due to reduced impairment of cognition and may reduce risks associated with opioids due to its analgesia sparing property. Although such a drug may have important benefits for ICU patients requiring sedation for greater than 24 hours, dexmedetomidine is not currently approved for such long-term usage.

02

Conditions studied

  • Mechanically Ventilated and Intubated Subjects

Keywords

  • Sedation, ICU, Anesthesia, Dexmedetomidine, Midazolam
03

In context

Lead sponsor

Hospira, now a wholly owned subsidiary of Pfizer is the lead sponsor of 28 studies on the registry; none are open to participants now.

First submitted before Hospira became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is ≥18 years of age.
  2. If female, subject is non-lactating, and is either:

    1. Not of , defined as for at least 1 year or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy, or hysterectomy.
    2. Of childbearing potential but is not pregnant as confirmed by negative serum pregnancy test at time of screening, and is practicing one of the following methods of : oral or parenteral contraceptives for three months prior to study drug administration, a vasectomized partner, or abstinence from sexual intercourse.
  3. Subject is initially intubated and mechanically ventilated, or is planned for imminent intubation and mechanical ventilation, sedation is anticipated to be required during mechanical ventilation, and mechanical ventilation is anticipated to continue for at least 72 hours.
  4. Subject or subject's legally authorized representative has voluntarily signed and dated an form, approved by the applicable Institutional Review Board (IRB), after the nature of the study has been explained and the subject or subject's legally authorized representative has had the opportunity to ask questions. The informed consent must be signed before any study specific procedures are performed.
  5. Subject is sedated within a Richmond Agitation-Sedation Scale (RASS) range of -2 to +1 at the time of initiation of study drug

Exclusion criteria

Exclusion Criteria:

  1. Subject has been intubated for greater than 96 hours prior to the initiation of study drug (thus, the attainment of consent, screening evaluations, and randomization must all have been completed by the 96th hour post-intubation, so that the actual initiation of the study drug infusion may start by the end of the 96 hour window).
  2. Subject has serious central nervous system pathology/trauma that, per clinical judgment of the Investigator, precludes responsiveness or survival.
  3. Subject for whom opiates, benzodiazepines, or dexmedetomidine are , or who has known or suspected serious allergy to any drug that might be administered during the course of the study.
  4. Subject for whom alpha-2 agonists are contraindicated.
  5. Subject requires neuromuscular blocking agents during the study for use other than intubation.
  6. Subject requires epidural or spinal analgesia during the study.
  7. Subject meets any of the following cardiovascular criteria:

    • Acute unstable angina (defined during current hospital stay).
    • Suspicion of acute myocardial infarction.
    • Considered to have a of less than 30%. Decision to exclude is predicated on the Investigator's opinion, and may be based on any combination of acute presentations, recently performed diagnostic studies, or a history that suggests poor cardiac function. Pulmonary congestion of a non-cardiac origin or mild congestive failure primarily attributable to etiologies other than poor ventricular function are not exclusion criteria.
    • Heart rate \<50 bpm prior to infusion start.
    • Systolic blood pressure \<90 mmHg prior to infusion start.
    • Conduction abnormalities except 1st degree AV block and rate-controlled atrial fibrillation; subjects with functional pacemaker capacity may be enrolled.
  8. Subject is hospitalized primarily due to trauma and/or burns, has received general anaesthesia within the 24 hours prior to the start of study drug infusion, or is anticipated to require general anaesthesia within 24 hours after the start of the infusion.
  9. Subject has participated in a trial with any experimental drug within 30 days prior to enrollment in the study, or has ever been enrolled in this study.
  10. Subject is unable to undergo any procedure required by the protocol.
  11. Subject has laboratory results indicating the presence of liver disease consistent with a score >9 (Grade C).
  12. Subject has acute hepatitis, history or presence of chronic hepatitis, and/or has had a positive result for Surface Antigen Test.
  13. Subject requires dialysis (eg, hemodialysis, peritoneal dialysis, Continuous Venovenous Hemodialysis [CVVHD]).
  14. Subject has a known, uncontrolled seizure disorder.
  15. Subject has, per the Investigator's judgment, a known or suspected physical or psychological dependence on an abused drug, other than alcohol.
  16. Subject has a known psychiatric illness that could confound a normal response to sedative treatment.
  17. Subject is incarcerated.
  18. Subject is terminally ill with a life duration expectancy of ≤60 days.
  19. Subject has any other condition or factor which, in the Investigator's opinion, might increase the risk to the subject.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
420 participants (actual)

Study arms

  • Experimental
    Dexmedetomidine

    Drug: Dexmedetomidine HCL Injection

  • Active comparator
    Midazolam

    Drug: Midazolam Injection

06

What researchers measure

Primary outcomes

  1. The percentage of time spent within the protocol specified sedation range (Richmond Agitation-Sedation Scale [RASS] range of -2 to +1)

    RASS Range: Score +1 (Restless: Anxious; but movements not aggressive or vigorous) Score 0 (Alert and calm) Score -1 (Drowsy: Not fully alert, but has sustained awakening \[eye opening/eye contact\] to voice \[≥10 seconds\]) Score -2 (Light sedation: Briefly awakens with eye contact to voice \[\< 10 seconds\])

    Time frame: Preinfusion, Treatment period: every 10min for 30min, 1 & 4 hr after infusion starts, every 4 hrs, prior to end of infusion & extubation. Follow-up Period (48hrs): every 10min for 1st 30min after drug discontinuation, 1, 4, 8,12, 24 & 48 hr post infusion

Secondary outcomes

  1. Percentage of subjects able to achieve a RASS between - 2 and +1 without interruption of study drug

    Time frame: Preinfusion, Treatment period: every 10min for 30min, 1 & 4 hr after infusion starts, every 4 hrs, prior to end of infusion & extubation. Follow-up Period (48hrs): every 10min for 1st 30min after drug discontinuation, 1, 4, 8,12, 24 & 48 hr post infusion

  2. Percentage of subjects with evidence of delirium (Confusion Assessment Method [CAM]-ICU positive) while on study drug

    Time frame: Prior to the start of the study drug infusion. Daily each morning beginning the day after starting study drug, and at the end of study drug infusion.

  3. Percentage of subjects with evidence of delirium (CAM-ICU positive) following discontinuation of study drug

    Time frame: At 12, 24, 36, and 48 hrs after end of infusion. Every 12 hours during the 48-hour Follow-Up Period.

  4. Time to achieving a RASS between -2 and +1 for daily arousal assessment

    Time frame: Prior to the start of the study drug infusion. Daily each morning beginning the day after starting study drug, and at the end of study drug infusion.

  5. Percentage of subjects who can interact with caregivers

    Percentage of subjects who can interact with caregivers (i.e., follow at least 3 of the 4 arousal assessment commands) while in the protocol-specified RASS range of -2 to +1

    Time frame: Prior to start of infusion (Day 0), daily each morning throughout the Treatment Period beginning on the day after randomization (Study Day 1), and immediately prior to discontinuation of study drug infusion at the end of Treatment Period.

  6. Overall drug (sedative) tolerance

    Time frame: During the treatment period (Approximately 30 days)

  7. Fentanyl use

    Time frame: During the treatment period (Approximately 30 days)

  8. Nursing assessment

    Time frame: Screening period, during the treatment period (Approximately 30 days), and 48-hours of follow-up period

  9. Use of rescue midazolam for sedation

    Time frame: During the treatment period (Approximately 30 days)

07

Study locations

96 sites
  • Birmingham, Alabama 35294, United States
  • Chandler, Arizona 85248, United States
  • Phoenix, Arizona, United States
  • Scottsdale, Arizona 85258, United States
  • Rogers, Arkansas 72756, United States
  • Davis, California 95616, United States
  • Loma Linda, California 92354, United States
  • Palo Alto, California 94304, United States
  • Pasadena, California 91105, United States
  • Redlands, California 92373, United States
  • Sacramento, California 95819, United States
  • San Clemente, California 92672, United States
  • San Francisco, California, United States
  • San Jose, California, United States
  • Denver, Colorado 80204, United States
  • Farmington, Connecticut 06030, United States
  • New Haven, Connecticut 06520, United States
  • Newark, Delaware 19718, United States
  • Washington, District of Columbia 20010, United States
  • Bay Pines, Florida 33744, United States
  • Miami, Florida, United States
  • Orlando, Florida 32804, United States
  • Tampa, Florida 33606, United States
  • Atlanta, Georgia, United States
  • Augusta, Georgia 30909, United States
  • Gordon, Georgia 30905, United States
  • Arlington Heights, Illinois 60005, United States
  • Oak Park, Illinois 60302, United States
  • Peoria, Illinois 61603, United States
  • Indianapolis, Indiana, United States
  • Iowa City, Iowa 52242, United States
  • Kansas City, Kansas 66160, United States
  • Olathe, Kansas 66061, United States
  • Hazard, Kentucky 41701, United States
  • Louisville, Kentucky, United States
  • Alexandria, Louisiana 71301, United States
  • Shreveport, Louisiana, United States
  • Biddeford, Maine 04005, United States
  • Portland, Maine, United States
  • Baltimore, Maryland 21201, United States
  • Boston, Massachusetts 02115, United States
  • Flint, Michigan 48532, United States
  • Missoula, Montana, United States
  • Omaha, Nebraska 68131, United States
  • Camden, New Jersey 08103, United States
  • Englewood, New Jersey 07631, United States
  • Bronx, New York, United States
  • Brooklyn, New York 11215, United States
  • Buffalo, New York 14215, United States
  • Mineola, New York 11501, United States
  • New York, New York 10011, United States
  • Rochester, New York 14642, United States
  • Stoney Brook, New York 11794, United States
  • Syracuse, New York 13210, United States
  • Chapel Hill, North Carolina 27599, United States
  • Charlotte, North Carolina 28207, United States
  • Greensboro, North Carolina, United States
  • Winston-Salem, North Carolina, United States
  • Akron, Ohio 44307, United States
  • Dayton, Ohio 45429, United States
  • Kettering, Ohio 45429, United States
  • Toledo, Ohio, United States
  • Olkahoma City, Oklahoma 73104, United States
  • Medford, Oregon 97504, United States
  • Danville, Pennsylvania 17882, United States
  • Monroeville, Pennsylvania 15146, United States
  • Pittsburgh, Pennsylvania 15219, United States
  • Charleston, South Carolina 29425, United States
  • Spartanburg, South Carolina 29303, United States
  • Memphis, Tennessee 38163, United States
  • Dallas, Texas, United States
  • Galveston, Texas 77555, United States
  • Houston, Texas 77024, United States
  • Lubbock, Texas 79430, United States
  • Ogden, Utah 84403, United States
  • Lynchburg, Virginia 24501, United States
  • Morgantown, West Virginia 26505, United States
  • Madison, Wisconsin 53792, United States
  • Ciudad de Buenos Aires, Argentina
  • Blacktown, New South Wales 2148, Australia
  • Randwick, New South Wales 2031, Australia
  • Woodville, South Australia 5011, Australia
  • Hobart, Tasmania 7001, Australia
  • Box Hill, Victoria 3128, Australia
  • Heidelberg, Victoria 3084, Australia
  • Parkville, Victoria 3050, Australia
  • Perth, Western Australia 6000, Australia
  • Porto Alegre, RS 90020-090, Brazil
  • Porto Alegre, RS 90610-000, Brazil
  • Pedro de Toledo, San Paulo 04039-901, Brazil
  • Santo Andre, San Paulo 09190-610, Brazil
  • Sao Paulo, SP 01323-001, Brazil
  • Christchurch, 8001, New Zealand
  • Hastings, 4201, New Zealand
  • Palmerston North, 5301, New Zealand
  • Welling, 6002, New Zealand
08

References and documents

Publications

  • Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, Whitten P, Margolis BD, Byrne DW, Ely EW, Rocha MG; SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009 Feb 4;301(5):489-99. doi: 10.1001/jama.2009.56. Epub 2009 Feb 2. PubMed 19188334 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 31, 2005
First posted
Sep 22, 2005
Start
Mar 2005
CompletionActual
Aug 2007
Last update
Jul 23, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00216190
Responsible party
Sponsor
First posted
Sep 22, 2005
Start date
Mar 2005
Completion
Aug 2007
Last update
Jul 23, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion